Navigating the Federal Prescription Maze: How Medicare, Medicaid, and Other Government Programs Differ on Generic Drug Coverage

A Tale of Two Programs—and the Same Prescription

Consider two Americans who both take the same generic blood pressure medication. One is a 68-year-old retiree enrolled in Medicare Part D. The other is a 45-year-old low-income parent covered by Medicaid. The drug is identical. The FDA-approved active ingredient, the manufacturer, the dosage—all the same. Yet one person pays a $3 copayment per month, while the other pays $47. A third person, enrolled in a different Part D plan, pays nothing after meeting a deductible.

This is not an anomaly. It is the predictable result of a fragmented federal coverage landscape in which each program was designed with different populations, funding structures, and policy goals in mind. For the estimated 160 million Americans who rely on some form of government-sponsored prescription coverage, understanding these differences is an essential financial and health literacy skill.

Medicare Part D: The Tiered Formulary System

Medicare Part D is the federal program that provides outpatient prescription drug coverage for Americans 65 and older, as well as certain younger individuals with qualifying disabilities. Unlike Medicaid, Part D is not administered directly by the government. Instead, it is delivered through private insurance plans that contract with Medicare—and those plans have considerable latitude in how they structure their formularies.

Most Part D plans organize covered drugs into a tier system, typically ranging from Tier 1 to Tier 5 or higher. Generic medications are almost universally placed in Tier 1 or Tier 2, which carry the lowest cost-sharing requirements. Tier 1 generics often require only a nominal copayment—frequently between $1 and $10—while Tier 2 generics may cost slightly more. However, the specific drugs placed on each tier, and the cost-sharing amounts associated with them, vary significantly from plan to plan.

This means that a generic drug your neighbor pays $4 for under their Part D plan could cost you $20 under a different plan covering the same geographic area. Formulary design is a competitive tool, and plans use it to attract specific patient populations while managing their drug spend.

Another important Part D variable is the annual deductible. In 2024, the standard Part D deductible reached $545. Many plans apply this deductible only to higher-tier drugs, exempting Tier 1 generics entirely. But not all do. Before assuming your generic is immediately covered at the lowest cost-sharing level, it is worth reviewing your plan's specific deductible structure.

The Donut Hole: Still Relevant for Generic Users

The Affordable Care Act significantly restructured the Part D coverage gap—colloquially known as the "donut hole"—and the Inflation Reduction Act of 2022 further modified its impact. As of 2024, beneficiaries who reach the coverage gap pay no more than 25 percent of the cost for covered generic drugs while in that phase, with manufacturer discounts and government subsidies covering the remainder.

For patients who take multiple generic medications and reach the coverage gap, this 25 percent cost-sharing can still represent a meaningful out-of-pocket burden depending on the drug's list price. Generics with very low list prices—the $4 generics available at major retail chains—may be barely affected. However, specialty generics or recently patent-expired drugs with higher list prices can generate significant costs even at 25 percent.

The catastrophic coverage phase, which kicks in after total out-of-pocket spending reaches a threshold (set at $8,000 for 2024), eliminates cost-sharing entirely for the remainder of the plan year. Patients who reach this threshold—typically those with serious chronic conditions requiring multiple or expensive medications—pay nothing for covered drugs, including generics, for the rest of the year.

Medicaid: Broader Coverage, Narrower Formularies

Medicaid serves low-income Americans of all ages and is jointly funded by federal and state governments. Unlike Medicare Part D, Medicaid programs must cover a broad set of federally mandated drug categories, but states retain significant flexibility in how they structure their preferred drug lists (PDLs) and cost-sharing requirements.

For most Medicaid beneficiaries, generic drugs are either free or available for a nominal copayment—typically no more than $4 under federal cost-sharing caps for non-exempt populations. This makes Medicaid one of the most generous prescription coverage programs in the country for patients who qualify.

However, Medicaid's preferred drug lists can be more restrictive than Medicare Part D formularies in certain therapeutic categories. A generic that is readily covered under Part D may require prior authorization or step therapy under a state Medicaid program—meaning a patient must first try and fail on a less expensive alternative before the program will cover their preferred medication. This gatekeeping mechanism is designed to manage program costs but can delay access to clinically appropriate treatment.

Medicaid also operates supplemental rebate agreements with manufacturers, allowing states to negotiate additional discounts beyond the federal rebate floor. This means that the drugs on a state's PDL are not purely selected on clinical grounds—they also reflect which manufacturers have offered the most favorable rebate terms. The result is that Medicaid formularies can differ substantially from state to state, creating geographic disparities in drug access for a nominally national program.

The Low-Income Subsidy: Bridging the Medicare Gap

For Medicare beneficiaries with limited income and resources, the Low-Income Subsidy (LIS)—also called Extra Help—provides substantial financial assistance with Part D costs. LIS recipients pay dramatically reduced premiums, deductibles, and cost-sharing amounts. In many cases, full LIS beneficiaries pay $0 to $4 for generic medications regardless of which tier they occupy on the formulary.

Approximately 14 million Medicare beneficiaries qualify for LIS, yet a meaningful percentage of eligible individuals are not enrolled. The application process runs through the Social Security Administration and can be initiated online, by phone, or at a local Social Security office. State Medicaid agencies also automatically enroll certain dual-eligible beneficiaries—those who qualify for both Medicare and Medicaid—in the full LIS benefit.

For seniors who are not currently enrolled but believe they may qualify, applying for Extra Help is one of the highest-return actions available. The income and resource thresholds are more generous than many people assume, and even partial LIS eligibility can generate hundreds of dollars in annual savings on generic medications alone.

Other Federal Programs: VA, TRICARE, and FEHB

Veterans receiving care through the Department of Veterans Affairs access prescription drugs through the VA formulary, which is nationally uniform and heavily weighted toward generic medications. Copayments for generics are typically $11 per 30-day supply for most veterans, with exemptions for those with service-connected conditions, financial hardship, or other qualifying circumstances. The VA's formulary management is centralized and driven by clinical evidence and cost-effectiveness analysis, making it one of the most systematically managed drug benefit programs in the country.

TRICARE, which covers active-duty military members, retirees, and their families, offers generic drugs at no cost when obtained through military treatment facility pharmacies. The TRICARE Pharmacy Home Delivery program also provides generics at minimal cost. Retail network pharmacies charge slightly higher copayments, but the overall cost burden for generic medications under TRICARE remains well below commercial insurance averages.

The Federal Employees Health Benefits (FEHB) program covers current and retired federal civilian employees through a range of private plan options. Generic drug coverage under FEHB varies by plan but is generally structured similarly to commercial insurance, with Tier 1 generics available at low or no cost-sharing.

Practical Strategies for Government Program Enrollees

Regardless of which program covers you, several strategies can help maximize the value of your generic drug benefits.

Use the Medicare Plan Finder annually. During the open enrollment period each fall, compare Part D plans based on your specific medication list. The Plan Finder tool at medicare.gov calculates your estimated annual drug costs across all available plans in your area, accounting for formulary placement and tier structure.

Apply for Extra Help if you are anywhere near the income threshold. The LIS program is significantly underutilized, and eligibility rules are more flexible than many assume. Even a partial subsidy can meaningfully reduce your annual out-of-pocket costs.

Ask about Medicaid's prior authorization alternatives. If a preferred generic requires prior authorization, ask your prescriber to submit documentation supporting medical necessity. Many prior authorization requests are approved when accompanied by appropriate clinical rationale.

Explore dual eligibility. If you qualify for both Medicare and Medicaid, you may be a dual-eligible beneficiary entitled to enhanced benefits under both programs. Your state's Medicaid office can help determine your eligibility status and coordinate your benefits.

Compare retail pharmacy pricing against your plan's cost-sharing. For very low-cost generics, cash pricing programs at major pharmacy chains—or discount platforms like GoodRx—may occasionally undercut your plan's copayment, particularly if you have not yet met your deductible. However, purchases made outside your insurance plan do not count toward your out-of-pocket maximum, so this strategy requires careful calculation.

The Bottom Line

Government prescription programs represent some of the most powerful tools available to American consumers for managing medication costs—but only if you understand how they work. The differences between Medicare Part D, Medicaid, and other federal programs are not arbitrary; they reflect decades of distinct legislative priorities and funding mechanisms. Navigating them effectively requires the kind of program-specific knowledge that too few beneficiaries currently possess.

At GenericMeds USA, our commitment is to translate that complexity into actionable guidance. Whether you are a senior comparing Part D plans during open enrollment or a low-income patient trying to understand why your Medicaid formulary changed, the information you need to make informed decisions is available—and knowing where to look is half the battle.